Anastrozole + Trastuzumab Deruxtecan
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early-stage Breast Cancer
Conditions
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Trial Timeline
Oct 9, 2020 → Dec 31, 2026
NCT ID
NCT04553770About Anastrozole + Trastuzumab Deruxtecan
Anastrozole + Trastuzumab Deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Early-stage Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04553770. Target conditions include Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer.
What happened to similar drugs?
1 of 6 similar drugs in Early-stage Breast Cancer were approved
Approved (1) Terminated (1) Active (5)
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04553770 | Phase 2 | Recruiting |
Competing Products
9 competing products in Early-stage Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ICG | Johnson & Johnson | Pre-clinical | 26 |
| SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection | Jiangsu Hengrui Medicine | Phase 3 | 47 |
| Tamoxifen alone + Tamoxifen + Aminoglutethimide | AstraZeneca | Phase 3 | 40 |
| Cyclophosphamide + Methotrexate + Fluorouracil implant + Goserelin + Tamoxifen | AstraZeneca | Phase 3 | 40 |
| ABP 234 + Pembrolizumab | Amgen | Phase 3 | 47 |
| Rotigotine | UCB | Phase 3 | 40 |
| UCB0599 + Placebo | UCB | Phase 2 | 35 |
| Rasagiline + Pramipexole | Lundbeck | Approved | 32 |
| Neratinib + Loperamide + Colesevelam | Puma Biotechnology | Phase 2 | 29 |